drugset / Trial / NCT05879029

Clinical Study of Jinsang Liyan Capsules Combined With PPI in the Treatment of LPRD

NCT05879029

RandomizedParallel-groupDouble-blindTreatment

Summary

The goal of this clinical trial is to compare the efficacy of Jinsang Liyan capsule in combination with PPI versus PPI alone for the treatment of Laryngopharyngeal Reflux Disease (LPRD). Participants will be randomly assigned in a 1:1 ratio to the experimental group or the control group. The experimental group was treated with Jinsangliyan capsule + rabeprazole enteric-coated tablets, and the control group was treated with Jinsangliyan capsule placebo + rabeprazole enteric-coated tablets. Participants were followed up at 4 weeks and 8 weeks after taking the drug to evaluate the improvement of LPRD symptoms. Researchers will compare Experimental group and control group to see if Jinsang Liyan capsule combined with PPI treatment is superior to PPI treatment alone.

Timeline

Start
2023-07-01
Primary completion
2024-12
Completion
2024-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Jinsang Liyan Capsule Unknown 1.6 g Oral
Background Rabeprazole Small molecule 20 mg Oral